



Corcept Therapeutics Incorporated



CORT NASDAQ

Biotechnology

Market Capitalization USD:

\$261.03 mm

CONCERN LEVEL: AVERAGE

- 1 The CEO's total remuneration is within the typical market range for the relevant industry and market cap.
- 2 The ratio between the CEO's pay and the median pay of the other named executive officers is 3X or less.
- 3 The CEO's annual cash incentives rose or fell in line with annual performance.
- 4 The CEO received no more than one annual cash bonus this fiscal year.
- 5 The CEO's equity remuneration reflected the company's share price movement over the last five years.
- 6 The company only pays long-term incentives to the CEO for above median performance against a peer group.
- 7 The company's dilution from equity incentives is 10 percent or less. 
- 8 Unvested equity lapses when the CEO's employment is terminated. 
- 9 The CEO's potential cash severance payment is capped at two times annual cash remuneration.
- 10 The accrued benefits of the CEO's post-retirement income are within the typical market range for the relevant market cap bracket.

CEO: Joseph K. Belanoff

Age: 54

CEO Since: 1999

	2009	2010	2011
Base Salary	\$440,272	\$453,480	\$467,084
Discretionary Bonus	\$0	\$454,000	\$0
Annual Cash Incentive	\$0	\$0	\$0
Benefits and Perquisites	\$0	\$0	\$0
TOTAL ANNUAL COMPENSATION	\$440,272	\$907,480	\$467,084
Increase in Post-Retirement Benefits	\$0	\$0	\$0
Stock Option Awards	\$909,350	\$0	\$3,057,026
Stock Awards	\$0	\$0	\$0
TOTAL COMPENSATION	\$1,349,622	\$907,480	\$3,524,110
Median of Other Named Executive Officers Total Compensation	\$466,371	\$655,030	\$993,814
Value Realized on Exercise of Stock Option	\$0	\$0	\$0
Value Realized on Vesting of Stock	\$0	\$0	\$0
TOTAL REALIZED EQUITY COMPENSATION	\$0	\$0	\$0

Proxy Date: 21 May 2012

Annual Meeting Date: 13 Jun 2012

Equity Reserves: 17.97%

Stock Option Run Rate: 2.24%

Corcept Therapeutics Incorporated


CORT NASDAQ

Biotechnology

Market Capitalization USD: **\$261.03 mm**

Performance Comparison

■ S&P500 ■ Industry ■ CORT



Peer Comparisons (TRBC) =Biotechnology

Total Summary CEO Compensation

Ticker	Company Name	2009	2010	2011	Market Cap
CORT	Corcept Therapeutics Incorporated	\$1,349,622	\$907,480	\$3,524,110	\$261,030,636
PDLI	PDL BioPharma, Inc.	\$1,078,572	\$1,701,013	\$1,164,350	\$775,859,802
EXEL	Exelixis, Inc.	\$4,554,083	\$686,143	\$2,358,581	\$704,200,153
ISIS	Isis Pharmaceuticals, Inc.	\$2,128,436	\$1,749,841	\$1,897,332	\$675,700,786
AVEO	AVEO Pharmaceuticals, Inc.		\$1,517,123	\$2,027,545	\$663,316,064
GHDX	Genomic Health, Inc.	\$457,000	\$1,615,115	\$1,833,605	\$648,238,050
VIVO	Meridian Bioscience, Inc.	\$549,305	\$1,008,691	\$843,411	\$646,148,343

To insure consistency, peer comparisons are based on a combination of TRBC Industry and Sector classifications and company market caps.

Missing peer pay figures for 2011 are due to differences in company filing schedules.

Pay Peer Group

NA

Performance Peer Group

NA

COMPENSATION COMMITTEE MEMBERS

Director	Membership	Age	Gender	Tenure	Independence
G. Leonard Baker	Chairman	69	Male	13	Outside Related
David L. Mahonev	Member	57	Male	8	Outside
Joseph C. Cook	Member	70	Male	10	Outside Related

This report is for informational purposes only, and should not be considered a solicitation to buy or sell any security. Thomson Reuters Business Classification (TRBC) is a global industry classification system that is owned and operated by Thomson Reuters and has been licensed for use by GMI Ratings.

COPYRIGHT 2012 | GMI Ratings | ALL RIGHTS RESERVED